chasing
questions:

pt en
Menu

New type of blood cells work as indicators of autoimmunity

August 11, 2017

Researchers have found a specific type of immune regulatory cells that could soon be used as potential clinical biomarkers to diagnose certain autoimmune diseases.

The team from Instituto de Medicina Molecular (iMM) Lisboa, led by Luis Graça, analysed blood samples from Sjögren syndrome patients, an autoimmune disease that affects the mucous membranes and moisture-secreting glands of the eyes and mouth, and found that these patients have a significant increase in a specific type of immune cells called T follicular regulatory cells (Tfr).  

These cells are usually found in lymphoid tissues where they regulate antibody production. It was a surprise to find an increase of these type of cells in patients with excessive antibody production. In fact, the results now published in Science Immunology, were the opposite of what the team was expecting.

To understand the reason behind such unexpected results the researchers studied different biological samples. For instance, comparing Tfr cells in the blood and in the tissues where antibodies are produced (tonsils obtained from children subjected to tonsillectomies), provided evidence that blood Tfr cells are immature, not able to fully suppress antibody production. Such immaturity was confirmed by studying blood samples from other patients with genetic defects. Furthermore, exposure of healthy volunteers to flu vaccine led to an increase in blood Tfr cells, in line with their generation during immune responses with antibody production.

Blood circulating Tfr cells are distinguished from other circulating lymphocytes by two molecular markers, CXCR5 and FOXP3, the first of which endows these cells with the ability to migrate into specific zones of lymph nodes where they may complete maturation and regulate antibody production. 

The team is now trying to understand what happens to these cells in other autoimmune diseases to evaluate their potential not only for diagnostic but also to identify which patients may benefit with medicines that interfere with the production of harmful antibodies.

This site uses cookies. Some of the cookies we use are essential for parts of the site to operate and have already been set.
You may delete and block all cookies from this site, but parts of the site will not work.